February 17, 2022
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase healthspan and lifespan. The full press release is included here. NEW YORK, Feb. 16, 2022 /PRNewswire/ -- Cambrian Biopharma, a multi-asset longevity biotech, today announced a licensing...
February 03, 2021
Like nearly all conferences this past year, the 3rd Annual Longevity Therapeutics Summit, presented by Hanson Wade Limited, went virtual this time around. This was a stark difference from the previous two, which were rather fancy affairs in downtown San Francisco. However, we were fortunate that the organizers went forward with the event, bringing together...
November 18, 2019
ResTORbio announced on Friday 15th that its current phase 3 drug trial for respiratory tract infections did not achieve its primary goal. The drug showed promise in earlier phases of testing, but sadly failed to reduce the incidence of respiratory tract infections in patients aged 65 and above. A setback for RTB101 This news has...
April 16, 2019
Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it's named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved...
April 10, 2017
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis. PureTech have recently announced a joint venture with Novartis called resTORbio and are...